These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 19333704)

  • 41. Eyelid hypertrichosis associated with latanoprost is reversible.
    O'Toole L; Cahill M; O'Brien C
    Eur J Ophthalmol; 2001; 11(4):377-9. PubMed ID: 11820311
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Latanoprost and hyperpigmentation of eyelashes.
    Wand M
    Arch Ophthalmol; 1997 Sep; 115(9):1206-8. PubMed ID: 9298071
    [No Abstract]   [Full Text] [Related]  

  • 43. Intraocular pressure lowering efficacy of travoprost.
    Przydryga JT; Egloff C;
    Eur J Ophthalmol; 2004; 14(5):416-22. PubMed ID: 15506604
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A comparison of morning and evening instillation of a combination travoprost 0.004%/timolol 0.5% ophthalmic solution.
    Denis P; Andrew R; Wells D; Friren B
    Eur J Ophthalmol; 2006; 16(3):407-15. PubMed ID: 16761242
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Eyelash hypertrichosis induced by topical latanoprost: 6-month follow-up study.
    Stecchi G; Saccucci S; Molinari S; De Gregorio F
    Acta Ophthalmol Scand Suppl; 2002; 236():56-7. PubMed ID: 12390146
    [No Abstract]   [Full Text] [Related]  

  • 46. Incidence of deepening of the upper eyelid sulcus on treatment with a tafluprost ophthalmic solution.
    Sakata R; Shirato S; Miyata K; Aihara M
    Jpn J Ophthalmol; 2014 Mar; 58(2):212-7. PubMed ID: 24390604
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Twenty-four-hour intraocular pressure control with the travoprost/timolol maleate fixed combination compared with travoprost when both are dosed in the evening in primary open-angle glaucoma.
    Konstas AG; Mikropoulos D; Haidich AB; Ntampos KS; Stewart WC
    Br J Ophthalmol; 2009 Apr; 93(4):481-5. PubMed ID: 19019932
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Influence of switching to travoprost on intraocular pressure of uncontrolled chronic open-angle glaucoma patients compliant to previously-used topical medication.
    Holló G; Vargha P; Kóthy P
    Curr Med Res Opin; 2005 Dec; 21(12):1943-8. PubMed ID: 16368044
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intraocular pressure lowering efficacy and safety of travoprost 0.004% as a replacement therapy in patients with open angle glaucoma or ocular hypertension.
    Ge J; Sun XH; Wang NL; Zhao JL; Wu LL; Chen XM; Wang ZX; Li B
    Chin Med J (Engl); 2010 Jun; 123(11):1417-21. PubMed ID: 20819599
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
    Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
    Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A randomized, prospective study of bimatoprost 0.01% or travoprost/timolol in patients previously treated with latanoprost and timolol to reduce intraocular pressure.
    Nixon DR
    J Ocul Pharmacol Ther; 2013 Dec; 29(10):876-81. PubMed ID: 24070367
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucoma.
    Gandolfi S; Paredes T; Goldberg I; Coote M; Wells A; Volksone L; Pillai MR; Stalmans I; Denis P;
    Eur J Ophthalmol; 2012; 22(1):34-44. PubMed ID: 22167541
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Travoprost/timolol fixed combination in the management of open-angle glaucoma: a clinical review.
    Denis P
    Expert Opin Pharmacother; 2011 Feb; 12(3):463-71. PubMed ID: 21254951
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost.
    Aihara M; Otani S; Kozaki J; Unoki K; Takeuchi M; Minami K; Miyata K
    J Glaucoma; 2012 Jan; 21(1):60-4. PubMed ID: 21278589
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of travoprost 0.004% ophthalmic solution, six weeks after its laminated packaging had been removed, in primary open-angle glaucoma: a randomized, controlled, investigator-blinded study.
    Reis R; dos Santos LC; Vila MP; Magacho L
    Clin Ther; 2004 Dec; 26(12):2121-7. PubMed ID: 15823775
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma.
    Holló G; Chiselita D; Petkova N; Cvenkel B; Liehneova I; Izgi B; Berta A; Szaflik J; Turacli E; Stewart WC
    Eur J Ophthalmol; 2006; 16(6):816-23. PubMed ID: 17191187
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of the role of travoprost 0.004% ophthalmic solution in the management of open angle glaucoma and ocular hypertensive patients.
    Chiselită D;
    Oftalmologia; 2007; 51(2):81-6. PubMed ID: 17937041
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The comparison of the effects of latanoprost, travoprost, and bimatoprost on central corneal thickness.
    Zhong Y; Shen X; Yu J; Tan H; Cheng Y
    Cornea; 2011 Aug; 30(8):861-4. PubMed ID: 21499083
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Travoprost in children: adverse effects and intraocular pressure response.
    Yanovitch TL; Enyedi LB; Schotthoeffer EO; Freedman SF
    J AAPOS; 2009 Feb; 13(1):91-3. PubMed ID: 19233013
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.